SG10201506725QA - Sdf-1 binding nucleic acids and the use thereof in cancer treatment - Google Patents
Sdf-1 binding nucleic acids and the use thereof in cancer treatmentInfo
- Publication number
- SG10201506725QA SG10201506725QA SG10201506725QA SG10201506725QA SG10201506725QA SG 10201506725Q A SG10201506725Q A SG 10201506725QA SG 10201506725Q A SG10201506725Q A SG 10201506725QA SG 10201506725Q A SG10201506725Q A SG 10201506725QA SG 10201506725Q A SG10201506725Q A SG 10201506725QA
- Authority
- SG
- Singapore
- Prior art keywords
- sdf
- nucleic acids
- cancer treatment
- binding nucleic
- binding
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10009397 | 2010-09-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201506725QA true SG10201506725QA (en) | 2015-10-29 |
Family
ID=44653255
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201506725QA SG10201506725QA (en) | 2010-09-09 | 2011-09-09 | Sdf-1 binding nucleic acids and the use thereof in cancer treatment |
| SG2013011150A SG188220A1 (en) | 2010-09-09 | 2011-09-09 | Sdf-1 binding nucleic acids and the use thereof in cancer treatment |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013011150A SG188220A1 (en) | 2010-09-09 | 2011-09-09 | Sdf-1 binding nucleic acids and the use thereof in cancer treatment |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20130310442A1 (https=) |
| EP (1) | EP2613789B1 (https=) |
| JP (1) | JP6243736B2 (https=) |
| KR (1) | KR101937939B1 (https=) |
| CN (1) | CN103108641B (https=) |
| AU (1) | AU2011300818B2 (https=) |
| BR (1) | BR112013005664B8 (https=) |
| CA (1) | CA2810950C (https=) |
| DK (1) | DK2613789T3 (https=) |
| ES (1) | ES2678497T3 (https=) |
| MX (1) | MX357770B (https=) |
| RU (1) | RU2679495C2 (https=) |
| SG (2) | SG10201506725QA (https=) |
| WO (1) | WO2012031773A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011300818B2 (en) * | 2010-09-09 | 2015-11-12 | TME Pharma AG | SDF-1 binding nucleic acids and the use thereof in cancer treatment |
| EP3443095A1 (en) * | 2016-04-15 | 2019-02-20 | Noxxon Pharma AG | Method of modulating the number and the distribution of tumor-infiltrating leukocytes in tumors |
| WO2021261601A1 (ja) | 2020-06-26 | 2021-12-30 | ラクオリア創薬株式会社 | レチノイドとがん治療薬との併用療法が有効ながん患者の選択方法およびレチノイドとがん治療薬との併用医薬 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6011020A (en) | 1990-06-11 | 2000-01-04 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand complexes |
| US5840867A (en) | 1991-02-21 | 1998-11-24 | Gilead Sciences, Inc. | Aptamer analogs specific for biomolecules |
| US5582981A (en) | 1991-08-14 | 1996-12-10 | Gilead Sciences, Inc. | Method for identifying an oligonucleotide aptamer specific for a target |
| AU2855399A (en) | 1998-03-24 | 1999-10-18 | Chugai Seiyaku Kabushiki Kaisha | Vascularization inhibitors |
| ES2156581T5 (es) * | 1998-03-30 | 2015-01-21 | Northwest Biotherapeutics, Inc. | Aplicaciones terapéuticas y diagnósticas basadas en el papel del gen CXCR-4 en la tumorigénesis |
| US6395029B1 (en) | 1999-01-19 | 2002-05-28 | The Children's Hospital Of Philadelphia | Sustained delivery of polyionic bioactive agents |
| CA2412493C (en) * | 2000-06-26 | 2010-11-09 | Wellstat Biologics Corporation | Purging of cells using viruses |
| US6652886B2 (en) | 2001-02-16 | 2003-11-25 | Expression Genetics | Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents |
| US20060019917A1 (en) * | 2001-05-18 | 2006-01-26 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of stromal cell-derived factor-1 (SDF-1) gene expression using short interfering nucleic acid (siNA) |
| US7468253B2 (en) | 2001-06-07 | 2008-12-23 | Chemocentryx, Inc. | Method for multiple chemokine receptor screening for antagonists using RAM assay |
| CA2449628C (en) | 2001-06-07 | 2008-05-06 | Zheng Wei | Cell migration assay |
| EP1306382A1 (de) | 2001-10-26 | 2003-05-02 | Noxxon Pharma AG | Modifizierte L-Nukleinsäure |
| ATE469164T1 (de) | 2001-10-26 | 2010-06-15 | Noxxon Pharma Ag | Modifizierte l-nukleinsäure |
| WO2003070823A2 (en) | 2002-02-20 | 2003-08-28 | The General Hospital Corporation | Conjugates comprising a biodegradable polymer and uses therefor |
| JP2006524242A (ja) * | 2003-03-27 | 2006-10-26 | エモリー ユニバーシティー | Cxcr4アンタゴニストおよびそれらの使用方法 |
| NZ542687A (en) | 2003-04-13 | 2010-02-26 | Enzon Pharmaceuticals Inc | Polymeric oligonucleotide prodrugs |
| GB0314472D0 (en) | 2003-06-20 | 2003-07-23 | Warwick Effect Polymers Ltd | Polymer |
| CA2940803A1 (en) | 2004-03-23 | 2005-10-27 | Ascendis Pharma Gmbh | Prodrug linker |
| JP5107716B2 (ja) | 2004-11-05 | 2012-12-26 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア | 分子治療用生分解性リンカー |
| EP1883651A1 (en) * | 2005-05-26 | 2008-02-06 | Rappaport Family Institute For Research in the Medical Sciences | Polypeptides and compositions comprising same and methods of using same for treating cxcr4 associated medical conditions |
| US20070043012A1 (en) * | 2005-08-19 | 2007-02-22 | Bridger Gary J | Methods to enhance chemotherapy |
| KR101466931B1 (ko) * | 2006-07-18 | 2014-12-02 | 녹손 파르마 아게 | Sdf-1 결합형 b형 핵산분자 |
| JP5244785B2 (ja) * | 2006-08-11 | 2013-07-24 | 小野薬品工業株式会社 | ストローマ由来因子−1(sdf−1)に対するモノクローナル抗体 |
| MX2009002859A (es) | 2006-09-15 | 2009-03-30 | Enzon Pharmaceuticals Inc | Enlazadores biodegradables a base de ester impedido para suministro de oligonucleotidos. |
| WO2008077945A2 (en) * | 2006-12-22 | 2008-07-03 | Ablynx N.V. | Anti-chemokine (ccl2, ccl3, ccl5, cxcl11, cxcl12) single-domain antibodies |
| US8772257B2 (en) | 2007-08-06 | 2014-07-08 | Noxxon Pharma Ag | SDF-1 binding nucleic acids and the use thereof |
| AU2011300818B2 (en) * | 2010-09-09 | 2015-11-12 | TME Pharma AG | SDF-1 binding nucleic acids and the use thereof in cancer treatment |
-
2011
- 2011-09-09 AU AU2011300818A patent/AU2011300818B2/en active Active
- 2011-09-09 RU RU2013115739A patent/RU2679495C2/ru active
- 2011-09-09 DK DK11757776.7T patent/DK2613789T3/en active
- 2011-09-09 CN CN201180043233.4A patent/CN103108641B/zh active Active
- 2011-09-09 CA CA2810950A patent/CA2810950C/en active Active
- 2011-09-09 SG SG10201506725QA patent/SG10201506725QA/en unknown
- 2011-09-09 SG SG2013011150A patent/SG188220A1/en unknown
- 2011-09-09 US US13/821,669 patent/US20130310442A1/en not_active Abandoned
- 2011-09-09 EP EP11757776.7A patent/EP2613789B1/en active Active
- 2011-09-09 MX MX2013002722A patent/MX357770B/es active IP Right Grant
- 2011-09-09 ES ES11757776.7T patent/ES2678497T3/es active Active
- 2011-09-09 BR BR112013005664A patent/BR112013005664B8/pt active IP Right Grant
- 2011-09-09 JP JP2013527497A patent/JP6243736B2/ja active Active
- 2011-09-09 WO PCT/EP2011/004554 patent/WO2012031773A1/en not_active Ceased
- 2011-09-09 KR KR1020137006584A patent/KR101937939B1/ko active Active
-
2015
- 2015-11-20 US US14/947,173 patent/US9387221B2/en active Active
-
2016
- 2016-07-03 US US15/201,477 patent/US10093934B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN103108641B (zh) | 2016-01-13 |
| US9387221B2 (en) | 2016-07-12 |
| US20130310442A1 (en) | 2013-11-21 |
| JP2013540725A (ja) | 2013-11-07 |
| EP2613789B1 (en) | 2018-04-18 |
| BR112013005664B8 (pt) | 2023-04-25 |
| WO2012031773A1 (en) | 2012-03-15 |
| US20160095875A1 (en) | 2016-04-07 |
| SG188220A1 (en) | 2013-04-30 |
| CA2810950A1 (en) | 2012-03-15 |
| RU2679495C2 (ru) | 2019-02-11 |
| RU2013115739A (ru) | 2014-10-20 |
| ES2678497T3 (es) | 2018-08-13 |
| HK1184699A1 (zh) | 2014-01-30 |
| AU2011300818A1 (en) | 2013-03-07 |
| CN103108641A (zh) | 2013-05-15 |
| MX357770B (es) | 2018-07-24 |
| CA2810950C (en) | 2023-02-14 |
| BR112013005664B1 (pt) | 2021-11-03 |
| US20160355821A1 (en) | 2016-12-08 |
| BR112013005664A2 (pt) | 2020-08-04 |
| JP6243736B2 (ja) | 2017-12-06 |
| EP2613789A1 (en) | 2013-07-17 |
| DK2613789T3 (en) | 2018-07-23 |
| MX2013002722A (es) | 2013-06-28 |
| AU2011300818B2 (en) | 2015-11-12 |
| KR101937939B1 (ko) | 2019-01-11 |
| KR20130114094A (ko) | 2013-10-16 |
| US10093934B2 (en) | 2018-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201207574B (en) | Phytocannabinoids in the treatment of cancer | |
| IL222382A0 (en) | Robo1-fc fusion protein and use thereof for treating tumours | |
| LT2556071T (lt) | Kinazės inhibitoriai ir jų panaudojimas vėžio gydymui | |
| SG10201600632QA (en) | Sdf-1 binding nucleic acids and the use thereof | |
| GB201018014D0 (en) | Analytical methods and arrays for use in the same | |
| ZA201204423B (en) | Neuregulin antagonists and use thereof in treating cancer | |
| GB0921803D0 (en) | Drug composition and its use in therapy | |
| IL224766A (en) | Bard1 isoforms in lung and colorectal cancer and their uses | |
| SI2139917T1 (sl) | Anti-androgeni peptidi in njihove uporabe v zdravljenju raka | |
| IL226108B (en) | Mimochromes containing metals and their uses in chemistry and biology | |
| GB0919889D0 (en) | Drug composition and its use in therapy | |
| GB0921805D0 (en) | Drug composition and its use in therapy | |
| GB0919893D0 (en) | Drug composition and its use in therapy | |
| GB0910375D0 (en) | Drug composition and its use in therapy | |
| SG10201506725QA (en) | Sdf-1 binding nucleic acids and the use thereof in cancer treatment | |
| GB201718726D0 (en) | Phytocannabinoids in the treatment of cancer | |
| IL214565A0 (en) | Nucleic acids specifically binding with human factor vii/viia and uses thereof | |
| GB201015789D0 (en) | Peptides and their use in the treatment | |
| ZA201000446B (en) | SDF-1 binding nucleic acids and the use thereof | |
| HUP1000688A2 (en) | Use of trifluoro-phthalimides in the treatment of cancer | |
| GB0814920D0 (en) | Peptides and their use in treatment | |
| GB201021425D0 (en) | Drug composition and its use in therapy | |
| ZA201006197B (en) | Fence and clamp for use in the fence | |
| GB0921804D0 (en) | Drug composition and its use in therapy | |
| GB0918728D0 (en) | Drug composition and its use in therapy |